Last reviewed · How we verify
hepatitis A inactivated virus vaccine
This vaccine works by exposing the body to a small, harmless piece of the hepatitis A virus, prompting the immune system to produce antibodies that can fight the virus.
This vaccine works by exposing the body to a small, harmless piece of the hepatitis A virus, prompting the immune system to produce antibodies that can fight the virus. Used for Prevention of hepatitis A.
At a glance
| Generic name | hepatitis A inactivated virus vaccine |
|---|---|
| Sponsor | GlaxoSmithKline |
| Drug class | inactivated virus vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
The inactivated virus vaccine triggers an immune response, producing antibodies that can neutralize the hepatitis A virus. This provides long-term immunity against the virus, protecting against infection and disease.
Approved indications
- Prevention of hepatitis A
Common side effects
- Pain, redness, or swelling at the injection site
- Fatigue
- Headache
Key clinical trials
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-M (PHASE2)
- Pfs230D1 + R21 in Matrix-M1 in African School Children and Adults (PHASE2)
- Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants (PHASE2)
- Infant Malaria Vaccine Schedule Optimization (PHASE2)
- Immunogenicity and Safety of I-HAV in Healthy Thai Children and Adolescents Lacking Protective Antibody After L-HAV (PHASE3)
- Prospective Trial of Vaccine Responses in Childhood Cancer Survivors (PHASE2)
- To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine (VITHA-A) (PHASE3)
- Immunogenicity and Safety of Inactivated and Live-attenuated HAV Vaccine Among Thai Healthy Children and Adolescents (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- hepatitis A inactivated virus vaccine CI brief — competitive landscape report
- hepatitis A inactivated virus vaccine updates RSS · CI watch RSS
- GlaxoSmithKline portfolio CI